Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 4
1993 2
1994 5
1995 3
1996 3
1997 4
1998 4
1999 5
2000 8
2001 8
2002 28
2003 34
2004 43
2005 78
2006 105
2007 125
2008 152
2009 176
2010 222
2011 240
2012 334
2013 319
2014 306
2015 266
2016 301
2017 284
2018 279
2019 252
2020 236
2021 238
2022 176
2023 180
2024 196
2025 255
2026 182

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,458 results

Results by year

Filters applied: . Clear all
Page 1
A Pilot Study of Exenatide Actions in Alzheimer's Disease.
Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. Mullins RJ, et al. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950. Curr Alzheimer Res. 2019. PMID: 31518224 Free PMC article. Clinical Trial.
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer's Disease (AD). ...However, the analysis of secondary outcomes show …
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treatin …
Exenatide.
Bray GM. Bray GM. Am J Health Syst Pharm. 2006 Mar 1;63(5):411-8. doi: 10.2146/ajhp050459. Am J Health Syst Pharm. 2006. PMID: 16484515 Review.
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of exenatide are discussed. SUMMARY: Exenatide, derived from a compound found in the saliva of the Gila monster, is an incretin mimetic …
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosage and administration of exen …
Exenatide.
Barnett AH. Barnett AH. Drugs Today (Barc). 2005 Sep;41(9):563-78. doi: 10.1358/dot.2005.41.9.893704. Drugs Today (Barc). 2005. PMID: 16341288 Review.
Exenatide is the first in a new class of compounds that exhibit activity similar to the naturally occurring hormone glucagon-like peptide-1 (GLP-1). ...Exenatide is generally well tolerated; nausea is the most commonly reported side effect, but it can be significant …
Exenatide is the first in a new class of compounds that exhibit activity similar to the naturally occurring hormone glucagon-like pep …
Exenatide.
Barnett A. Barnett A. Expert Opin Pharmacother. 2007 Oct;8(15):2593-608. doi: 10.1517/14656566.8.15.2593. Expert Opin Pharmacother. 2007. PMID: 17931093 Review.
Exenatide is the first in a new class of compounds, which possess similar activity to the naturally-occurring hormone glucagon-like peptide-1 (GLP-1). ...Exenatide is generally well tolerated; nausea is the most commonly reported side effect, but can be significantl …
Exenatide is the first in a new class of compounds, which possess similar activity to the naturally-occurring hormone glucagon-like p …
A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults.
Patino LR, Strawn JR, Adler CM, Blom TJ, Welge JA, DelBello MP. Patino LR, et al. J Affect Disord. 2025 Aug 1;382:116-122. doi: 10.1016/j.jad.2025.04.046. Epub 2025 Apr 7. J Affect Disord. 2025. PMID: 40203970 Clinical Trial.
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults with stable major mood or psychotic disorders were randomized to double-blind exenatide or placebo for 16 weeks. ...CONCLUSIONS: Exe …
OBJECTIVE: To assess the safety and efficacy of exenatide in overweight or obese patients treated with olanzapine. METHODS: Adults wi …
Exenatide.
Keating GM. Keating GM. Drugs. 2005;65(12):1681-92; discussion 1693-5. doi: 10.2165/00003495-200565120-00008. Drugs. 2005. PMID: 16060703
Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5microg (in two studies) or 10microg (in all three studies). Post hoc completer analyses revealed that the beneficial effects of exenatide on HbA(1c) an …
Relative to placebo, reductions from baseline in bodyweight were significantly greater with twice-daily exenatide 5microg (in two stu …
Exenatide implant therapy in diabetes.
Kalra S, Saboo B. Kalra S, et al. J Pak Med Assoc. 2018 Oct;68(10):1538-1540. J Pak Med Assoc. 2018. PMID: 30317359 Review.
ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it's …
ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exen …
Long-acting preparations of exenatide.
Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W. Cai Y, et al. Drug Des Devel Ther. 2013 Sep 5;7:963-70. doi: 10.2147/DDDT.S46970. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 24039406 Free PMC article. Review.
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. ...This review summarizes recent advances in long-acting exenatide preparations....
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has li …
Exenatide and weight loss.
Bradley DP, Kulstad R, Schoeller DA. Bradley DP, et al. Nutrition. 2010 Mar;26(3):243-9. doi: 10.1016/j.nut.2009.07.008. Nutrition. 2010. PMID: 20152707 Review.
METHODS: A search through PubMed was performed using exenatide and weight loss as search terms. A second search was performed using exenatide and mechanisms or actions as search terms. RESULTS: In addition to exenatide's action to increase insulin secr …
METHODS: A search through PubMed was performed using exenatide and weight loss as search terms. A second search was performed using …
Exenatide. Amylin/Eli Lilly.
Giannoukakis N. Giannoukakis N. Curr Opin Investig Drugs. 2003 Apr;4(4):459-65. Curr Opin Investig Drugs. 2003. PMID: 12808888 Review.
Amylin Pharmaceuticals Inc and Eli Lilly & Co are co-developing exenatide (AC-2993; synthetic exendin-4), a 39-amino acid, glucagon-like peptide-1 agonist derived from the venom of the Gila monster lizard (Heloderma suspectum) as a potential injectable treatment for ty …
Amylin Pharmaceuticals Inc and Eli Lilly & Co are co-developing exenatide (AC-2993; synthetic exendin-4), a 39-amino acid, glucag …
4,458 results